Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus Chemotherapy with or without Bevacizumab in Advanced Cervical Cancer
NCT05446883Phase 3Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2022
- Primary completion
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of iparomlimab, tuvonralimab in Cervical Cancer (CC), sponsored by Qilu Pharmaceutical. Status: unknown.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05446883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05446883.